Self-Administered Intravesical Hyaluronic Acid Improves Symptoms and Quality of Life in a Patient-Centred Approach To Bladder Pain Syndrome Management
Main Article Content
Abstract
Background and Objectives
Bladder pain syndrome (BPS) is an uncommon and potentially debilitating spectrum of chronic pain typically accompanied by lower urinary tract symptoms. Intravesical hyaluronic acid (HA) is a commonly used treatment option, but requires multiple follow-up clinic appointments. We introduced a novel patient-led ‘at-home’ pathway of self-administered HA treatment to reduce the number hospital visits required by patients.
We assessed and compared patient-reported outcome measures (PROMS) from patients receiving nurse-administered ‘in-hospital’ and patient-led self-administered ‘at-home’ intravesical HA (Cystistat® and Hyacyst®, respectively). Secondary outcome measures included differences between waiting times for treatment, frequency of treatments, number of clinician and nurse clinic appointments, and estimated financial costs.
Patients and Methods
Sixty consecutive patients commencing intravesical HA for BPS symptoms between 1st January 2016 and 31st March 2019 were included. O’Leary-Sant Interstitial Cystitis Symptom Index questionnaires were completed prior to, and following, six treatments. Relevant clinical and demographic data were also collected.
Results
Overall, 76.6% of the patients had improvement in symptoms after HA treatment. Mean O’Leary-Sant questionnaire symptom and problem scores were significantly improved following HA treatment (11.8 (range 6–17) to 8.5 (range 4–13) (p=0.00005) and 11.4 (range 4–16) to 7.9 (range 4–14) (p=0.0002), respectively. There were no significant differences in symptom improvements between patients on either pathway.
Mean waiting time for treatment and number of treatments were lower in the patient-led pathway, and number of hospital visits was significantly lower in the patient-led at home pathway. The patient-led pathway could ‘save’ approximately 76 nurse clinic and 11 outpatient clinic appointments per year, and confer cost-savings of more than £1,500 per patient, per year.
Conclusions
Our case series analyses suggest that patient-led ‘at-home’ intravesical HA administration (Hyacyst®) is acceptable to patients and confers similar symptomatic benefit to ‘in-hospital’ nurse-led HA (Cystistat®). In addition, it appears that BPS sufferers established on the patient-led pathway require fewer HA treatments and fewer hospital visits, and as such, the patient-led pathway may also confer financial cost savings, and relieve some pressures on clinic appointment availability.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
References
2. Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 2011 August;186(2):540–44.
3. Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T, Wein A. Bladder Pain Syndrome Commit-tee of the International Consultation on Incontinence. Neurourol Urodyn 2010;29(1):191–8.
4. Cervigni M and Natale F. Gynecological disorders in bladder pain syndrome/interstitial cystitis patients. Int J Urol 2014 Apr; 21 Suppl 1:85–8.
5. Nickel JC and Tripp DA; International Interstitial Cystitis Study Group. Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. J Urol 2015 Jan; 193(1):138–44.
6. McKernan LC, Walsh CG, Reynolds WS, Crofford LJ, Dmochowski RR, Williams DA. Psychosocial co-morbidities in Interstitial Cystitis/Bladder Pain syndrome (IC/BPS): A systematic review. Neurourol Urodyn 2018 Mar; 37(3):926–41.
7. Grundy L, Caldwell A, Brierley SM. Mechanisms underlying overactive bladder and interstitial cystitis/ painful bladder syndrome. Front Neurosci 2018 Dec 12(12):931.
8. Hurst R, Greenwood-Van Meerveld B, Wisniewski AB, Van-Gordon S, Lin HK, Kropp BP, Towner RA. Increased bladder permeability in interstitial cystitis/ painful bladder syndrome. Transl Androl Urol 2015 Oct; 4(5):563–71.
9. Offiah I, Didangelos A, Dawes J, et al. The expression of inflammatory mediators in bladder pain syndrome. Eur Urol 2016 Aug; 70(2): 283–90.
10. Iavazzoa C, Athanasiouab S, Pitsounia E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007 June; 51(6): 1534–41.
11. Lazzeri M, Hurle R, Casale P, et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol 2016 Apr;8(2):91–9.
12. Wyndaele JJJ, Riedl C, Taneja R, Lovász S, Ueda T, Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn 2019 Feb;38(2):535–44.
13. Engeler D, Baranowski AP, Berghmans B, et al. EAU Guidelines. Edn. presented at the EAU Annual Con-gress Barcelona 2019.
14. Han E, Nguyen L, Sirls L, Peters K. Current best practice management of interstitial cystitis/ bladder pain syndrome. Ther Adv Urol 2018 Jul; 10(7): 197–11.
15. O’Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symp-tom index and problem index. Urology 1997 May; 49(5A Suppl):58–63.
16. Jeremy Stangroom. T Test Calculator. Social Science Statistics. Available at: https://www.socscistatistics .com/tests/studentttest/default.aspx
17. Pumps. Ilias W, Le Polain B, Buchser E, Demartini L. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programable The oPTiMa study group. Pain Practice 2008 May/June (8);3:164–170.
18. Chakravarthy K, Chaudhry H, Williams K, Christo PJ. Review of the uses of vagal nerve stimulation in chronic pain management. Curr Pain Headache Rep Dec 2015;19:54.
19. McCorkle R, Ercolano E, Lazenby M, et al. Self-management: Enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin 2011 January/February (61);1:50–62.
20. Hoffman AJ. Enhancing self-efficacy for optimized patient outcomes through the theory of symptom self-management. Cancer Nurs 2013 Jan;36(1):E16–E26.
21. Roditi D and Robinson ME. The role of psychologi-cal interventions in the management of patients with chronic pain. Psychol Res Behav Manag 2011;4:41–9.
22. Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/ chondroitin sulfate instillation for interstitial cystitis/ painful bladder syndrome. Cell Physiol Biochem 2016;39(4):1618–25
23. National Health System. 2017/18 and 2018/19 National Tariff Payment System. Available at: https://improvement. nhs.uk/resources/national-tariff-1719/#h2-tariff-documents.
24. Tu FF, Kane JN, Hellman KM. Noninvasive experimental bladder pain assessment in painful bladder syndrome. BJOG 2017 Jan;124(2):283–91.